title: Further characterization of a clinically relevant model of melanoma metastasis and an effective vaccine.
abstract: A major problem in evaluating the effectiveness of tumor cell vaccination and other biological therapies is the variability of experimental models. In this study we have further developed and characterized a model for metastatic melanoma that approximates the major clinical stages of metastatic dissemination: stage I--growth of the primary (local) tumor, stage II--dissemination to regional lymph nodes, and stage III--metastasis to distant organs (lungs). C57BL/6 mice were challenged subcutaneously with B16 F10 murine melanoma cells in the midtail, and within 3 weeks 100% of the mice had local tumors growing in their tails. By 5-7 weeks after challenge, most of the mice had developed metastases to the inguinal lymph nodes and subsequently had metastatic colonies in the lungs and in the bone marrow. Preimmunization of mice with a formalinized extracellular antigen vaccine, derived from B16 F10 melanoma cells, provided partial inhibition of the growth of the primary melanoma tumors, as well as reducing the number of metastases to the regional (inguinal) lymph nodes and lungs along with concomitantly increasing survival time. This model for melanoma metastasis provides a reasonable and reproducible test system for the study of anti-melanoma immunity and the different cellular and humoral mechanisms involved.
authors.affiliation: Department of Pathology, Roger Williams Cancer Center, Brown University, Providence, RI 02908, USA.
authors.forename: D
authors.initials: D
authors.lastname: Shrayer
authors.forename: H
authors.initials: H
authors.lastname: Bogaars
authors.forename: V J
authors.initials: VJ
authors.lastname: Hearing
authors.forename: A
authors.initials: A
authors.lastname: Maizel
authors.forename: H
authors.initials: H
authors.lastname: Wanebo
mesh_terms: D000818:Animals; D000912:Antibodies, Neoplasm / Q000096:biosynthesis; D000951:Antigens, Neoplasm / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D016233:Immunotherapy, Active; D007279:Injections, Subcutaneous; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008546:Melanoma, Experimental / Q000276:immunology / Q000556:secondary* / Q000628:therapy; D058950:Melanoma-Specific Antigens; D051379:Mice; D008810:Mice, Inbred C57BL; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000276:immunology / Q000627:therapeutic use*; D009368:Neoplasm Transplantation / Q000379:methods; D013623:Tail
chemical_list: D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; C094440:formalinized extracellular antigen